Author

admin

Browsing

Congressional Democrats remained skeptical that any progress toward an end to the war in Ukraine would be made ahead of the meeting between President Donald Trump and Russian President Vladimir Putin.

The high-stakes meeting in Anchorage, Alaska, comes as lawmakers have grown anxious to see an end to the conflict between Russia and Ukraine, and with many ready to slap a bone-breaking sanctions package on Moscow and its allies unless Putin relents.

But Democrats are not so sure that Trump will yield results in his closed-door meeting with Putin, the first between U.S. and Russian leaders since the invasion of Ukraine in 2022.

‘I fear this meeting could once again end with America ceding ground to an autocrat who has spent his career undermining democratic values,’ Sen. Mark Warner, D-Va., and the top Democrat on the Senate Intel Committee, said.

He warned that there could be no concessions without Ukraine’s involvement, Russia’s withdrawal from Ukrainian territory and ‘enforceable guarantees’ for Ukraine’s security.

‘Anything less would be an invitation for further aggression from Moscow and every autocrat watching to see if the United States still has the backbone to defend the principles that have kept Americans safe since the Second World War,’ he said.  

House Minority Leader Hakeem Jeffries, D-N.Y., accused Trump of previously ‘playing footsie’ with Putin, but noted that it appeared that the president’s disposition toward his Russian counterpart had shifted.

He added that last year, House Democrats and Republicans worked together to pass another military aid package for Ukraine, and likened it to a ‘Churchill or Chamberlain moment.’

‘We are either going to appease the dictator or we’re going to aggressively oppose the dictator,’ Jeffries said. ‘And as we saw with Chamberlain, appeasing the dictator never works.’

Trump himself sought to set expectations for the summit, telling Fox News Radio earlier this week that there would be a 25% chance that the meeting would end in failure.

And aboard Air Force One, Trump told reporters that he wanted to ‘see a ceasefire rapidly.’

‘I don’t know if it’s going to be today, but I’m not going to be happy if it’s not today,’ he said. ‘Everyone said it can’t be today, but I’m just saying I want the killing to stop.’

The Trump administration has threatened to slap secondary tariffs on India, a major buyer of Russian oil, if the meeting did not go well. That comes after Trump gave Putin a 50-day deadline to reach a ceasefire agreement, which the president recently shortened to ’10 or 12′ days.

Sen. Jeanne Shaheen, the top Democrat on the Senate Foreign Intelligence Committee, told reporters that ‘people have been willing to give the White House and the president the benefit of the doubt.’

‘But if he doesn’t produce anything at this summit, after drawing red line after red line … there will be growing concern and a growing pressure to try and get something done,’ the New Hampshire Democrat said.

One area where many lawmakers in the upper chamber agree is the necessity for a sanctions package against Russia. Currently, Sens. Lindsey Graham, R-S.C., and Richard Blumenthal, D-Conn., have a bill in the works that would slap up to 500% tariffs on countries buying energy products from Moscow.

Blumenthal told MSNBC earlier this week if Trump stood firm and insisted on a ceasefire, Putin come to the table with European leaders and secure security guarantees ‘he has the makings of a potential agreement that could win him the Nobel Peace Prize.’

‘But my fear is that he will be the mercurial Donald Trump who allowed the deadline for sanctions to pass last Friday without any imposition of new levies on Russia, and that he will fail to adhere to those principles adopted yesterday by the European countries in their meeting,’ he said. 

This post appeared first on FOX NEWS

As President Donald Trump greeted Russian President Vladimir Putin on the tarmac at Joint Base Elmendorf-Richardson, a B-2 stealth bomber soared overhead, flanked by four F-35 jets. 

Putin looked up at the sky as the planes buzzed overhead while he walked alongside Trump, and then made a comment to the U.S. president. 

The display was as much a symbol as it was a show of force—a pointed reminder of America’s military reach at the very moment the two leaders prepared to discuss the future of global security.

The dramatic arrival underscored the high-stakes nature of the Alaska summit, the first face-to-face meeting between Trump and Putin since Trump’s return to the White House earlier this year. Joint Base Elmendorf-Richardson, situated just outside Anchorage, was chosen for its robust security, strategic location, and symbolic position—physically closer to Russia than Washington, D.C., yet firmly on American soil.

Onlookers in Anchorage and across social media quickly seized on the moment. Many called it an ‘insane flex,’ noting the B-2 bomber’s recent combat history.

Only two months ago, the stealth aircraft played a central role in U.S. and Israeli strikes on Iranian nuclear facilities, dropping bunker-buster bombs in a move that drew both praise and condemnation on the world stage.

The B-2 Spirit, built by Northrop Grumman, is one of the most advanced aircraft ever created—capable of penetrating dense air defenses and striking targets anywhere in the world without refueling. Its distinctive flying-wing design and radar-absorbent coating make it nearly invisible to enemy radar. 

With a range of over 6,000 nautical miles and the ability to carry both conventional and nuclear weapons, the B-2 serves as a critical component of America’s nuclear triad. Only 21 were ever built, and fewer than 20 remain in service, making any public appearance a rare and deliberate statement.

‘Absolutely incredible,’ wrote one X user. Another added, ‘Putin now knows what will be greeting him if he were to ever cross that line that should never be crossed.’

After the brief tarmac ceremony, Putin entered ‘The Beast’ alongside Trump. The heavily armored presidential limousine rolled past a row of American fighter jets lined up in silent formation, their presence another visual reminder of the stakes surrounding the talks.

The two leaders traveled to a secure meeting hall on the base, beginning discussions at about 3:30 p.m. Eastern Time. Trump has said he plans to ‘set the table’ during the meeting for a future summit that includes Ukrainian President Volodymyr Zelenskyy. But still, he told Fox News’ Bret Baier he ‘won’t be happy’ if Putin does not agree to a ceasefire in Ukraine. 

This post appeared first on FOX NEWS

Ukrainian President Volodymyr Zelenskyy said on Saturday he will travel to Washington, D.C. on Monday to meet with President Donald Trump.

Zelenskyy’s announcement comes a day after Trump met with Russian President Vladimir Putin in Alaska on Friday to negotiate an end to the war in Ukraine.

‘On Monday, I will meet with President Trump in Washington, D.C., to discuss all of the details regarding ending the killing and the war. I am grateful for the invitation,’ Zelenskyy wrote on X.

This is a breaking news story. Check back for updates.

This post appeared first on FOX NEWS

Russian President Vladimir Putin said he agreed with Donald Trump’s claim that the war in Ukraine would not have ever even begun if he had not lost the 2020 election and was serving as president when the carnage began, instead of former President Joe Biden.  

‘I can confirm that,’ Putin said at the tail-end of a press conferece that took place Friday evening after the pair met for a summit at Joint Base Elmendorf-Richardson in Anchorage, Alaska. 

Trump made the assertion multiple times on the campaign trail, and continued saying it after he took back the White House. Trump has faced pushback on the claim, as well as on claims that Ukraine instigated the war’s inception and the Biden administration failed to do things that could have thwarted it from beginning in the first place.

‘I’d like to add one more thing,’ Putin said, as the two heads of state provided remarks to the press, according to a translation of the Russian president’s address. ‘I’d like to remind you that in 2022, during the last contact with a previous administration, I tried to convince my previous American colleague that the situation should not be brought to a point of no return when it would come to hostilities and I said it quite directly back then that it’s a big mistake. Today, when President Trump is saying that if he was the president back then there would be no war – I am quite sure that it would indeed be so. I can confirm that.’

Earlier in his address, Putin lamented that bilateral relations between the U.S. and Russia, prior to Trump, had ‘fallen to the lowest point since the Cold War,’ and highlighted the fact that there have been no summits between the U.S. and Russia over the last four years.

‘That’s not benefiting our counties and the world as a whole,’ Putin said, adding that it was ‘apparent that sooner or later [U.S. and Russia] had to amend the situation to move on from the confrontation to dialogue.’

Meanwhile, Putin praised Trump for ‘his strive to get to the crux of the matter and to understand this history,’ referring to the backstory surrounding the war. He called the commitment ‘precious.’ 

The Russian president also remarked during his address that he hopes this new chapter of foreign diplomacy under Trump will ‘help us rebuild and foster mutually beneficial and equal ties at this new stage, even during the hardest conditions.’

‘Overall, me and President Trump have built a very good business-like and trustworthy contact, and have every reason to believe that moving down this path we can come to the end of the conflict in Ukraine,’ Putin said Friday. 

The optics of Trump’s meeting with Putin were slammed by critics, who compared the scene Friday to when Ukrainian President Volodymyr Zelenskyy met with Trump at the White House. 

The infamous meeting saw Zelenskyy publicly argue back-and-forth with Trump and other top leaders in the administration, as President Trump criticized the Ukrainian president for his approach to ending the war.

‘Biden could’ve stopped it, Zelenskyy could’ve stopped it, and Putin should’ve never started it,’ Trump said in April about the war in Ukraine.

This post appeared first on FOX NEWS

It was a made-for-TV moment: The two leaders met on the tarmac at Joint Base Elmendorf–Richardson in Anchorage, Alaska, Air Force One and two F-35 fighters in the background. As they walked together, overhead came the roar of those F-35s, followed by the low, almost ghostly sweep of a B-2 stealth bomber — a display of U.S. airpower as much as a nod to the Cold War history between the nations.

Hours later, after their closed-door discussions, President Donald Trump and Russian President Vladimir Putin appeared again — this time on a raised stage, each behind a podium, U.S. and Russian flags flanking both sides, with a blue backdrop behind them that read ‘Pursuing Peace.’ It was the first U.S.-hosted summit between American and Russian presidents on U.S. military soil.

Trump had spent days rehearsing via secure calls with European leaders and Ukrainian President Volodymyr Zelenskyy, coordinating ‘red lines’ to take into the meeting: no territorial concessions to Russia, Ukraine in the room for all negotiations, and clear conditions for any sanctions relief. Yet, despite the military pomp and the careful stagecraft, what emerged from Alaska was not a deal, but a diplomatic pause — warm words, thin details, and the hard work still ahead.

Putin spoke first, describing the talks as ‘constructive and mutual respect.’ He recalled moments in history when the U.S. and Russia ‘worked together’ and said he sought a ‘long-term settlement.’ He acknowledged Russia’s ‘legitimate concerns’ and said it was ‘very important for our countries to turn the page.’ He described a ‘trustworthy tone’ in the conversation and praised Trump for having ‘a good idea of what he wants.’ In a line clearly aimed at the cameras back home, Putin claimed Trump told him that if he had been president earlier, ‘there would not have been war,’ and confirmed that he believed it was true.

Trump followed, also taking no questions. ‘We had productive meetings,’ he said. ‘Big agreements. No deal until there is a deal.’ He promised to call ‘NATO,’ to ‘call Zelenskyy,’ and declared, ‘We really made great progress today.’ He reminded the audience of his ‘fantastic relationship with Putin’ and judged there was ‘a good chance of getting there,’ even if ‘we’re not there yet.’ Most importantly, Trump said, ‘We need to stop thousands of people being killed every week.’

For all the positive tone, the substance was modest. Putin left Alaska dangling the prospect of a ceasefire — but with strings attached. We know from prior statements that he wants the U.S. to lift certain sanctions and drop tariff threats aimed at countries like India that buy Russian energy. He intends to keep control of two eastern Ukrainian provinces seized in 2022. Likely, Trump did not concede those points, but evidently they agreed to a follow-on meeting ‘soon.’ 

While the flags fluttered in Anchorage, the war did not stop. Russian forces pressed forward modestly near Dobropillia in Donetsk region, testing Ukrainian defenses in what looks like an attempt to improve their tactical position before any pause. Ukraine rushed reinforcements, stabilizing the line for now, but fighting remains intense.

Russia’s long-range bombardment shows no sign of abating. In July alone, Moscow launched more than 70 cruise missiles and thousands of Iranian-made Shahed drones at Ukrainian targets. Ukraine has answered with deep strikes — including a hit on a Russian oil refinery and the bombing of a cargo ship carrying drone parts in the Caspian Sea. Neither side is behaving as if the war’s end is imminent.

That’s why any ceasefire talk must be backed by ironclad verification: neutral observers on the ground, satellite surveillance, clearly mapped lines, and automatic ‘snap-back’ sanctions for violations. Without that, Moscow will have every incentive to rearm under the cover of diplomacy.

If nothing else, Alaska revealed the bottom lines.

For Putin, it’s about locking in territorial gains and relieving the economic pressure eroding his war machine. Rolling back sanctions on countries that help him skirt restrictions would boost his revenues and signal to others that U.S. economic warfare is negotiable.

For Trump, it’s about testing whether Putin can be moved toward de-escalation without sacrificing U.S. credibility. Involving Zelenskyy keeps Ukraine’s fate from being decided in absentia, and reaffirming NATO’s support reassures allies.

For Ukraine, it’s a double-edged sword. A follow-on meeting offers a diplomatic opening, but Putin’s explicit territorial demands remain a political, legal, and moral red line.

Washington must resist trading sanctions relief for vague promises. The sanctions regime is one of the few levers that works, and any easing must be tied to measurable, sustained compliance verified by independent intelligence as well as neutral monitors.

Putin leaves Alaska with the optics of being a willing negotiator — useful for his domestic image — but no immediate relief on sanctions or Western recognition of his land grabs. Expect him to probe Western unity with limited escalations in the next two weeks.

Kyiv has a brief window to reinforce its defenses and prepare a clear case for the next meeting: explicit security guarantees, timetables for arms deliveries, and a non-negotiable stance on sovereignty.

Allied capitals can point to a small win: the U.S. did not cut a side deal. But they must be ready to step up enforcement and fill any gaps if U.S. resolve wavers.

Beijing will study Alaska closely. If the West blinks on sanctions enforcement, it could embolden Chinese adventurism in the Pacific. A unified Western stand would send the opposite message.

If the U.S. wants these ceasefire talks to go anywhere, three steps are essential:

  1. Lock in Enforcement MechanismsBuild a monitoring framework that combines neutral observers, allied intelligence, and technological oversight. Make violations costly and automatic to deter cheating.
  2. Keep Ukraine at the Center‘No decision about Ukraine without Ukraine’ must remain non-negotiable. Zelensky needs a real voice and veto over any territorial terms.
  3. Use Sanctions as Leverage, Not CurrencyAny relief should be phased, conditional, and reversible. Sanctions should be the reward for sustained compliance, not an upfront concession.

The Alaska summit was not the breakthrough some hoped for, but it wasn’t a failure, either. It gave both sides a clearer picture of the negotiating terrain and bought time for positioning. But time favors the side that uses it best.

For the United States, that means holding firm on sanctions, bolstering Ukraine’s defenses, and treating any ceasefire as the start of a rigorous verification process, not the war’s conclusion. For Ukraine, it means preparing for two divergent paths: meaningful diplomacy or intensified conflict. For Russia, it means deciding whether continued war is worth the mounting cost when the West refuses to pay in land.

If Alaska was merely a pause, the next meeting will decide whether it becomes a bridge to peace — or a bridge to nowhere.

This post appeared first on FOX NEWS

Ukrainian President Volodymyr Zelenskyy on Saturday outlined firm conditions for a ‘real peace’ ahead of a high-stakes meeting with President Donald Trump on Monday.

Zelenskyy posted to X following his call with Trump and then with European leaders, after Trump and Russian President Vladimir Putin met in Alaska to try and bring about an end to the 3 ½ year war.

‘The positions are clear. A real peace must be achieved, one that will be lasting, not just another pause between Russian invasions,’ Zelenskyy wrote.

‘Killings must stop as soon as possible, the fire must cease both on the battlefield and in the sky, as well as against our port infrastructure. All Ukrainian prisoners of war and civilians must be released and the children abducted by Russia must be returned.’

Zelenskyy wrote that thousands of Ukrainians remain in captivity and must all be released, while adding that pressure on Russia must be maintained while the ‘aggression and occupation continue.’

In a follow-up post, Zelenskyy warned of Russian ‘treachery’ that could lead to attacks in order to gain leverage amid ongoing negotiations.  

‘Based on the political and diplomatic situation around Ukraine, and knowing Russia’s treachery, we anticipate that in the coming days the Russian army may try to increase pressure and strikes against Ukrainian positions in order to create more favorable political circumstances for talks with global actors,’ he wrote. 

Zelenskyy is scheduled to meet with Trump in the White House on Monday as the three nations try and bring an end to the bloodshed.

Trump wrote on Truth Social following the Putin meeting that he felt a peace agreement, rather than a ceasefire, was ultimately the best way to solve the war. Trump had been calling for a ceasefire ahead of his meeting with Putin. 

‘It was determined by all that the best way to end the horrific war between Russia and Ukraine is to go directly to a Peace Agreement, which would end the war, and not a mere Ceasefire Agreement, which often times do not hold up,’ Trump wrote.

He said if Monday’s meeting with Zelenskyy also goes well, a meeting will be scheduled with Putin and ‘potentially, millions of people’s lives will be saved.’

Zelenskyy’s visit will mark his first return to the Oval Office since February, when Trump berated him publicly for being ‘disrespectful’ during a remarkable press briefing, which led to the collapse of a U.S.-Ukraine minerals deal.

Though a peace agreement was not decided upon during the meeting on Friday, Trump described it as a successful meeting with ‘a lot of progress’ made. Putin expressed similar sentiments, adding the summit was a ‘constructive atmosphere of mutual respect.’

After his meeting with Putin, Trump also spoke to European leaders, who said they back Trump’s peace push but insist Ukraine must have ‘ironclad’ security guarantees to defend its sovereignty and territorial integrity.

The European leaders did not address whether a peace deal was preferable to a ceasefire.

‘It will be up to Ukraine to make decisions on its territory. International borders must not be changed by force,’ a statement signed by various leaders, including French President Emmanuel Macron, U.K. Prime Minister Keir Starmer and European Commission President Ursula von der Leyen.

‘No limitations should be placed on Ukraine’s armed forces or on its cooperation with third countries. Russia cannot have a veto against Ukraine‘s pathway to EU and NATO.’

During an interview with Fox News before returning to Washington, Trump insisted the onus going forward might be on Zelenskyy ‘to get it done,’ but said there would also be some involvement from European nations.

Fox News’ Elizabeth Pritchett and The Associated Press contributed to this report. 

This post appeared first on FOX NEWS

Here’s a quick recap of the crypto landscape for Wednesday (August 15) as of 9:00 a.m. UTC.

Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ethereum price update

Bitcoin (BTC) was priced at US$117,981, following a volatile 24 hours. Its lowest valuation of the day was US$117,547, while its highest so far was US$119,315.

Bitcoin price performance, August 15, 2025.

Chart via TradingView

Bitcoin surged to a new all-time high of $124,533 on Thursday (August 14), driven by expectations of Federal Reserve rate cuts and increased institutional interest. However, the rally was short-lived, as the price fell as low as $117,263 early Friday.

The decline was attributed to a higher-than-expected US Producer Price Index (PPI) for July, which dampened investor optimism about imminent interest rate reductions. Additionally, comments from US Treasury Secretary Scott Bessent revealed that the US holds fewer Bitcoin reserves than previously thought, further unsettling the market.

Meanwhile, Ethereum’s (ETH) weekend rally briefly has worn off, currently down by 3 percent to US$4,556.55. The cryptocurrency’s lowest valuation on Friday was US$4,462.52, and its highest was US$4,690.57.

Altcoin price update

  • Solana (SOL) was priced at US$189.85, down by 4.3 percent over 24 hours. Its highest valuation of the day was at US$198.27, while its lowest valuation was US$188.80.
  • XRP was trading for US$3.08, down 1.7 percent in the past 24 hours. Its highest valuation of the day was at US$3.14, while its lowest was US$3.04.
  • Sui (SUI) was trading at US$3.75, down by 2.53 percent over the past 24 hours. Its highest valuation of the day was at US$3.78, while its lowest was US$3.68.
  • Cardano (ADA) was trading at US$0.9485, up by 1.7 percent over 24 hours. Its highest valuation of the day was at US$0.9605, while its lowest was US$0.9362.

Today’s crypto news to know

Ethereum ETFs cruise past Bitcoin, totals nearly US$3 billion in a week

Ethereum-focused exchange-traded funds have seen an unprecedented surge in investor demand, attracting almost US$3 billion in net inflows over the past week.

According to SoSoValue data, this growth is more than five times the US$562 million that flowed into Bitcoin ETFs during the same period. The spike coincides with a rapid increase in Ethereum holdings by crypto treasury firms, which climbed from US$600 million to US$11 billion in just six weeks.

ETF Store president Nate Geraci noted that three of the four largest single-day inflows for Ethereum ETFs since their inception occurred this week alone.

ETH prices have rallied nearly 19 percent over the past seven days, coming within reach of their 2021 all-time high of US$4,878.

The inflows also follow recent SEC approval of in-kind creations and redemptions for spot Bitcoin and Ethereum ETFs, a change that makes the funds more cost-efficient and attractive to institutional investors.

Michael Saylor bets on US$100 billion ‘bitcoin credit’

Michael Saylor, executive chairman of Strategy (NASDAQ:MSTR) (formerly MicroStrategy), is pursuing a high-risk plan to finance further Bitcoin purchases through perpetual preferred stock offerings.

The new securities—nicknamed “Stretch”—do not mature, lack voting rights, and can skip dividends under certain conditions, giving the issuer flexibility while raising investor concerns about risk.

This marks a departure from the company’s earlier reliance on common stock sales and convertible bonds to fund what is now a US$75 billion Bitcoin treasury. Saylor aims to retire billions in outstanding debt and replace it with preferred equity, which he says could theoretically scale to US$100 billion or more in capital raised.

The model hinges on investor appetite for yield backed indirectly by Bitcoin’s performance, while avoiding the dilution impact of issuing more common stock.

Hong Kong SFC rolls out stricter rules for licensed Crypto platforms

Hong Kong’s Securities and Futures Commission (SFC) has introduced new custody rules for licensed virtual asset trading platforms, setting stricter benchmarks for how client assets must be stored and secured.

The updated framework includes specific requirements for cold wallet usage, senior management accountability, and real-time cyber-threat monitoring, alongside rules for using third-party wallet providers.

These measures follow an SFC review earlier this year that identified security and operational gaps among some licensed exchanges. The regulator says the changes are part of its ASPIRe strategy, a five-point plan to address liquidity fragmentation, regulatory arbitrage, and volatility while expanding regulated product offerings.

The policy also aims to position Hong Kong as a safer, more structured alternative to other Asian crypto hubs, notably Singapore, which has imposed tighter limits on retail trading.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year’s FDA approvals include Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. ABVC BioPharma (NASDAQ:ABVC)

Year-to-date gain: 405.95 percent
Market cap: US$50.61 million
Share price: US$2.98

ABVC BioPharma is a clinical-stage biopharma firm building a pipeline of products targeting a broad range of indications in ophthalmology, oncology, hematology and central nervous system (CNS) disorders.

It is advancing on six drugs and one medical device. ABVC in-licenses biotechnologies from research institutions such as Stanford University, the University of California at San Francisco and Cedars-Sinai Medical Center.

In mid-April, ABVC reported its 2024 financial results, highlighting total revenues of US$509,589 in 2024, representing 234 percent growth year-on-year. The company attributed this increase to milestone payments collected from its global licensing partners in the CNS, oncology and ophthalmology therapeutic areas.

This positive news provided a good base of support for ABVC’s share price, which started the year out at US$0.64, but by the end of April had pushed through the US$1 level.

Developments later in the summer gave the stock a further boost to the upside. On June 6, ABVC announced that its affiliate OncoX BioPharma is set to acquire the Lycopenoid Lycogen platform, including patented manufacturing technology and commercialization rights, from Asia-Pacific Biotech Developing.

‘OncoX’s acquisition of the Lycogen platform further enhances ABVC Group’s position in botanical oncology innovation,’ said ABVC CEO Dr. Uttam Patil in a press release at the time. ‘This transaction strengthens our pipeline and demonstrates our ability to convert platform assets into monetizable growth.’

In July, ABVC received a US$150,000 cash licensing payment from AiBtl BioPharma, one of its strategic partners. It represents a key milestone toward the company’s commercialization of its drug candidates ABV-1504 and ABV-1505, which are now under late-stage development for major depressive disorder and ADHD, respectively. Both of these drug candidates have active investigational new drug designations from the FDA.

That same month, the company received a US$100,000 milestone licensing payment from its licensing partner ForSeeCon Eye, which is working to develop and commercialize drugs for ophthalmic indications. This brought its cumulative licensing revenue across its strategic partnerships with AiBtl, OncoX and ForSeeCon to US$946,000.

Shares of ABVC reached a year-to-date high of US$4.74 on July 8.

2. I-Mab (NASDAQ:IMAB)

Year-to-date gain: 282.35 percent
Market cap: US$231.3 million
Share price: US$3.37

I-Mab is a global biotech firm developing precision immuno-oncology agents for the treatment of cancer.

The company’s lead candidate in its drug pipeline is givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers. Givastomig has the potential to treat other solid tumors.

I-Mab traded below US$1 for much of the year before getting a boost in Q3 from positive news flow.

On June 26, the company announced positive data from a Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers. This included a strong objective response rate and favorable safety profile. A few days later, it shared the publication of the first-in-human monotherapy data for givastomig in Clinical Cancer Research, a journal of the American Association for Cancer Research.

On July 17, I-Mab signed a definitive agreement to acquire 100 percent ownership of Bridge Health Biotech. This will give I-Mab the rights to bi-specific and multi-specific applications based on the Claudin 18.2 parental antibody used in givastomig. I-Mab expects to present a topline readout of its Phase 1b dose expansion in Q1 2026.

Shares of I-Mab hit a year-to-date high of US$3.37 on August 5.

3. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 180.92 percent
Market cap: US$232.91 million
Share price: US$3.68

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein.

Belapectin has been granted fast-track designation by FDA. Galectin’s lead development program, the NAVIGATE Phase 2b/3 trial, is evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension.

In May, the company presented positive topline data from the study at the European Association for the Study of the Liver 2025 Congress. Results included a significant reduction in new esophageal varices at 18 months and fewer patients experiencing worsening liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

In early July, Galectin announced a US$10 million unsecured line of credit facility with its largest individual stockholder and board chair, Richard E. Uihlein. It is expected to fund development work through June 2026.

Galectin’s share price peaked at US$3.68 on August 5.

4. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

CytomX kicked off 2025 at US$1.06, but spent much of the first two quarters on a slow slide to a year-to-date low of US$0.43 on April 7. The stock shot up to US$2.50 on May 13 after a series of announcements.

The day prior, CytomX provided its first quarter business update, which included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer.

The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. CytomX’s goal is to initiate a Phase 2 study in advanced colorectal cancer in the first half of 2026.

At the same time, the company closed on a US$100 million underwritten offering of common stock.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) KEYTRUDA (pembrolizumab) in patients with metastatic melanoma.

Shares of CytomX hit a year-to-date high of US$2.99 on June 12.

5. Gossamer Bio (NASDAQ:GOSS)

Year-to-date gain: 129.21 percent
Market cap: US$475.2 million
Share price: US$2.16

Gossamer Bio is focused on the development and commercialization of therapies to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The clinical-stage biopharma company’s lead drug candidate, seralutinib, is currently being evaluated in a Phase 3 clinical trial for the treatment of pulmonary arterial hypertension.

Gossamer Bio’s stock value received a bump from US$1.30 to US$1.45 on March 14.

The day prior, the company shared a business update, including news that a topline data readout for its Phase 3 study of seralutinib in pulmonary arterial hypertension was on track for the fourth quarter of 2025.

On June 16, Gossamer Bio announced it had completed enrollment for an ongoing Phase 3 study on pulmonary arterial hypertension, with topline data expected out in February 2026.

On August 5, the company reported that it expects to activate the first clinical sites for a global registrational Phase 3 study on pulmonary hypertension associated with interstitial lung disease patients in Q4 2025.

Shares of Gossamer Bio hit a year-to-date high of US2.16 on August 5.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Brien Lundin, editor of Gold Newsletter, shares his thoughts on gold and silver prices, as well as what types of stocks he’s focusing on in these sectors.

In his view, the precious metals are set up for a new era.

Click here to sign up for the New Orleans Investment Conference, hosted by Lundin.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; ‘ BRW ‘ or the ‘ Company ‘) is pleased to announce the consolidation of its ownership covering a group of eight mining claims at the Mirage project pursuant to a purchase and sale agreement dated August 15, 2025, with General Partnership Osisko Baie James (‘Osisko Baie James’). Brunswick Exploration now owns 100% of the mining claims across the Mirage project.

To acquire such rights, Brunswick has agreed to renounce to its option to acquire a 90% undivided interest in the Plex property, pursuant to the third amendment to option agreement, dated August 15 2025, between Brunswick and Osisko Baie James.

In partial consideration for the termination of the Plex Property Option pursuant to this Third Amendment Agreement, Osisko Baie James shall pay to Brunswick Exploration an amount of $1,000,000 to be paid within thirty (30) days of the first publication of a technical report prepared in accordance with the requirements of Regulation 43-101 presenting a minimum of 1M oz in gold in Measure, Indicated and/or Inferred resources (as those terms are defined in National Instrument 43-101).

Grant of DSU

The Corporation announces that it has granted 821,425 deferred share units (‘DSUs’) to its non-executive directors, in accordance with the Corporation’s Deferred Share Unit Plan, available on SEDAR+ at www.sedarplus.ca. in lieu of their board fees. The DSUs were granted at a fair market value of $0.14 per DSU and will vest one year from the grant date.

About Brunswick Exploration

Brunswick Exploration is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. The Company is focused on grassroots exploration for lithium in Canada, a critical metal necessary to global decarbonization and energy transition. The company is rapidly advancing its extensive grassroots lithium property portfolio in Canada and Greenland.

Investor Relations/information

Mr. Killian Charles, President and CEO ( info@BRWexplo.com )

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com